John J.P. Kastelein, MD PhD, FESC
Professor of Medicine
Dept. of Vascular Medicine
Academic Medical Center / University of Amsterdam
John J.P. Kastelein, MD PhD, FESC
John J.P. Kastelein (1954) is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease.
He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine.
Then, between 1986 and 1988, he
was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver
under the guidance of Prof.Dr.
Dr. Kastelein was president of the Dutch Atherosclerosis Society (DAS) until 2009 and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC).
He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society.
He also is a board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS) and Fellow of the European Society of Cardiology.
was also one of the founders of Amsterdam Molecular Therapeutics Inc.
(AMT), a gene therapy company based on the concept of gene replacement in hereditary lipoprotein disorders.
has recently (summer 2007) enjoyed a successful Initial Public Offering (IPO) at EuroNext in Amsterdam.
The results of the first successful human gene therapy trial were widely publicized in the media and are published in ATVB in 2008.
current research interests can be found in the etiology, diagnosis, prevention and treatment ofhypertriglyceridaemia, hypercholesterolaemia and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease.
He has published over 680 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 72.
Dr. Kastelein is an investigator of the Bloodomics and CardioGenics consortia, two large European Union supported endavours under the Framework Programme 7, that aim to elucidate the molecular basis of atherosclerosis and premature coronary disease.
Besides the scientific programmes aimed at the etiology of atherogenesis, Dr. Kastelein also serves on a number of executive and steering committees of large intervention studies, including the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008) and JUPITER (2008) are published in the New England Journal of Medicine, IDEAL (2006) in JAMA and RADIANCE 2 (2007) in Lancet.
Since recently, Dr. Kastelein
has developed the use of non-invasive B-mode ultrasound as well as Nuclear Magnetic Resonance (MRI) studies of the carotid arteries for the diagnosis and assessment of novel treatments for atherosclerosis.
This has lead to the recognition of the AMC
as a leading center for this technique which has recently been exported to a substantial number of academic sites throughout Europe.
This has culminated in the set up of NICE, Network of Imaging Centers
in Europe of which Dr. Kastelein
is the director.
achievements in this field are internationally recognized by numerous invited reviews on this subject.
Dr. Kastelein also serves as an International Associate Editor of the European Heart Journal.
has directed 47 postdoctoral theses and currently, he
heads a team of 6 internists, 6 postdoctoral fellows, 26 MD PhD students, and a large number of laboratory technicians and clinical trial / study coordinators